Literature DB >> 15059729

Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy.

Kazuaki Nishijima1, Masayo Takahashi, Joh Akita, Hideto Katsuta, Mai Tanemura, Hiroko Aikawa, Michiko Mandai, Hitoshi Takagi, Junichi Kiryu, Yoshihito Honda.   

Abstract

PURPOSE: To evaluate the efficacy of laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathic lesions.
DESIGN: Interventional case series.
METHODS: Fifteen eyes of 14 consecutive patients with idiopathic polypoidal choroidal vasculopathy lesions treated by laser photocoagulation of indocyanine green angiographically identified feeder vessels were investigated.
RESULTS: In 10 of the 15 eyes, serous retinal detachment of sensory retina in the macula disappeared after photocoagulation of the feeder vessels. The best-corrected visual acuity improved by 2 or more lines in eight of the 15 eyes and worsened in two eyes during the mean follow-up period of 13.6 months.
CONCLUSIONS: Laser photocoagulation targeted exclusively to the feeder vessels supplying the idiopathic polypoidal choroidal vasculopathy lesions is a safe and effective method and can improve vision in eyes in which a serous retinal detachment is present in the macula. Indocyanine green angiography-guided laser photocoagulation should be considered as an optional treatment for idiopathic polypoidal choroidal vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059729     DOI: 10.1016/j.ajo.2003.09.059

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy.

Authors:  Akiko Okubo; Motoko Ito; Taro Kamisasanuki; Taiji Sakamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-11       Impact factor: 3.117

3.  Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment.

Authors:  Ju Byung Chae; Joo Yong Lee; Sung Jae Yang; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2011-03-11

4.  The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Authors:  Lan-Hsin Chuang; Yih-Shiou Hwang; Nan-Kai Wang; Yen-Po Chen; Laura Liu; Ling Yeung; Kuan-Jen Chen; Tun-Lu Chen; Wei-Chi Wu; Chi-Chun Lai
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-20       Impact factor: 2.671

Review 5.  Polypoidal choroidal vasculopathy: Pearls in diagnosis and management.

Authors:  Giridhar Anantharaman; Jay Sheth; Muna Bhende; Raja Narayanan; Sundaram Natarajan; Anand Rajendran; George Manayath; Parveen Sen; Rupak Biswas; Alay Banker; Charu Gupta
Journal:  Indian J Ophthalmol       Date:  2018-07       Impact factor: 1.848

Review 6.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

Review 7.  Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options.

Authors:  Ana Rita Fernandes; Aleksandra Zielińska; Elena Sanchez-Lopez; Tiago Dos Santos; Maria Luisa Garcia; Amelia M Silva; Jacek Karczewski; Eliana B Souto
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

8.  Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Authors:  Kikushima Wataru; Atsushi Sugiyama; Seigo Yoneyama; Mio Matsubara; Yoshiko Fukuda; Ravi Parikh; Yoichi Sakurada
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.